ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Recombinant Human Prourokinase for Injection (rhPro-UK)

Its studies are mostly in Ischemic Stroke, led by China Resources Pharmaceutical Group.

Furthest: phase 3, since Nov 11, 20261 company-led study, 1 open or runningNext primary completion: Mar 1, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Resources Pharmaceutical Group11 open or runningphase 3since Nov 11, 2026Nov 11, 2026Mar 1, 2029phase 3 · NCT07942584

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2026First study: phase 3 study in Acute Ischemic Stroke AISFirst studyNCT07942584 · 978 planned · China

Ahead

  1. Mar 1, 2029Primary completion: phase 3 study in Acute Ischemic Stroke AISNCT07942584

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07942584Acute Ischemic Stroke AIS · China3Not yet recruitingMar 1, 2029978

How it is read

Names in the registry

  • “Recombinant Human Prourokinase for Injection (rhPro-UK)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 18, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.